Syros Pharmaceuticals, Inc. (SYRS)
Restoring healthy gene expression and myeloid differentiation. At Syros Pharmaceuticals, we're on a mission to offer hope to patients with blood disorders through biologically targeted solutions.
Syros Pharmaceuticals, Inc. (SYRS) - Yahoo Finance
Find the latest Syros Pharmaceuticals, Inc. (SYRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary …
20 hours ago · Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, tamibarotene, for treating higher-risk myelodysplastic syndrome (HR-MDS ...
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial …
2 days ago · CAMBRIDGE, Mass., November 12, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Syros Pharmaceuticals Shares Plummet Premarket After Study …
2 days ago · Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer. Syros ...
Investor Relations :: Syros Pharmaceuticals, Inc. (SYRS)
3 days ago · Syros is driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, and we aim to develop new standards of care for the frontline treatment of patients with hematologic malignancies.
Syros Pharmaceuticals Inc (SYRS) Stock Price & News - Google
Get the latest Syros Pharmaceuticals Inc (SYRS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
About Us :: Syros Pharmaceuticals, Inc. (SYRS)
Rooted in a deep understanding of how genes are controlled, our approach represents a new and unexploited field for drug discovery and development. Targeted drug discovery to date has focused largely on inhibiting or otherwise changing the function of abnormal genes and proteins.
News - Syros Pharmaceuticals, Inc.
Apr 9, 2024 · In January 2023, the FDA granted Fast Track Designation to tamibarotene for the treatment of HR-MDS patients with RARA overexpression. Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Syros Pharmaceuticals Inc. - MarketWatch
2 days ago · Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609.